Literature DB >> 10922203

Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study.

S Dithmar, D Rusciano, M J Lynn, D H Lawson, C A Armstrong, H E Grossniklaus.   

Abstract

OBJECTIVES: To investigate the treatment of metastasis from uveal melanoma and to test the effect of interferon (IFN) alfa-2b in a murine model.
METHODS: The B16-LS9 tissue culture melanoma cells were inoculated into the posterior intraocular compartment of 3 groups of C57BL/6 mice. The inoculated eyes were enucleated at 9 days and the mice were euthanized at 26 days after inoculation; the site and number of metastases were determined using standard histologic techniques. Group 1 was the control group; group 2 was given 20,000 international units (IU) of IFN alfa-2b intramuscularly 12 hours before enucleation, and group 3 received daily injections of 20,000 IU of IFN alfa-2b intramuscularly starting 4 days before enucleation.
RESULTS: Pulmonary metastases were detected in 57%, 33%, and 0% of groups 1, 2, and 3, respectively; hepatic micrometastases were detected only in group 1. These results showed a significant decrease in hepatic metastases in mice receiving IFN alfa-2b vs controls (P =.005).
CONCLUSION: Treatment with IFN alfa-2b results in decreased hepatic metastases from intraocular melanoma in a murine model. Arch Ophthalmol. 2000;118:1085-1089

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10922203     DOI: 10.1001/archopht.118.8.1085

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  17 in total

1.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

Review 2.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 3.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

Review 4.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

5.  [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].

Authors:  E Richtig; G Langmann; G Schlemmer; K Müllner; G Papaefthymiou; P Bergthaler; J Smolle
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

6.  NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice.

Authors:  Wanhua Yang; Haochuan Li; Elizabeth Mayhew; Jessamee Mellon; Peter W Chen; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-11       Impact factor: 4.799

Review 7.  Regulating surgical oncotaxis to improve the outcomes in cancer patients.

Authors:  Toshihiro Hirai; Hideo Matsumoto; Hisako Kubota; Yoshiyuki Yamaguchi
Journal:  Surg Today       Date:  2013-06-05       Impact factor: 2.549

8.  Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.

Authors:  Susan Achberger; Wayne Aldrich; Raymond Tubbs; John W Crabb; Arun D Singh; Pierre L Triozzi
Journal:  Mol Immunol       Date:  2013-12-25       Impact factor: 4.407

9.  The relation between c-myc expression and interferon sensitivity in uveal melanoma.

Authors:  P N Tulley; M Neale; D Jackson; J S Chana; R Grover; I Cree; A O Grobbelaar; G D Wilson
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

10.  Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells.

Authors:  Powrnima Joshi; Mitra Kooshki; Wayne Aldrich; Daniel Varghai; Maciej Zborowski; Arun D Singh; Pierre L Triozzi
Journal:  Clin Exp Metastasis       Date:  2016-08-26       Impact factor: 4.510

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.